62507-85-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-methylphenoxy)benzoic acid is used as an intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and properties.
Used in Agrochemical Industry:
4-(3-methylphenoxy)benzoic acid serves as a key component in the development of agrochemicals, contributing to the production of effective pesticides and other agricultural products.
Used in Dye Industry:
4-(3-methylphenoxy)benzoic acid is utilized in the creation of dyes, taking advantage of its chemical properties to produce a range of colorants for various applications.
Used in Cosmetics Industry:
As a UV stabilizer, 4-(3-methylphenoxy)benzoic acid is used in sunscreen products to protect against harmful ultraviolet radiation, enhancing the stability and effectiveness of these formulations.
Used in Antimicrobial Applications:
Due to its ability to inhibit the growth of various microorganisms, 4-(3-methylphenoxy)benzoic acid is applied in antimicrobial formulations to prevent the spread of bacteria and other pathogens.
Used in Medical Research:
4-(3-methylphenoxy)benzoic acid is under investigation for its potential use in the treatment of certain types of cancer, highlighting its possible role as a therapeutic agent in oncology.

InChI:InChI=1/C14H12O3/c1-10-3-2-4-13(9-10)17-12-7-5-11(6-8-12)14(15)16/h2-9H,1H3,(H,15,16)

Upstream product

• 78303-11-4 methyl 4-(3'-methylphenoxy)benzoate 
• 17933-03-8 m-tolylboronic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 61343-84-8 4-(m-tolyloxy)benzaldehyde 
• 108-39-4 3-methyl-phenol 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 1436378-54-9 N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(3-methylphenoxy)benzamide 
• 1377995-68-0 C₂₃H₃₀N₂O₂ 

Relevant academic research and scientific papers

Identification of highly potent N-acylethanolamine acid amidase (NAAA) inhibitors: Optimization of the terminal phenyl moiety of oxazolidone derivatives

N-acylethanolamine acid amidase (NAAA) is a cysteine hydrolase that participates in the deactivation of fatty acid ethanolamides, such as palmitoylethanolamide (PEA). NAAA inhibition may provide a potential therapeutic strategy for the treatment of diseases in which higher PEA level is desired. In the present study, we reported the structure-activity relationship (SAR) studies for oxazolidone derivatives as NAAA inhibitors. A series of substituents or alkyl replacements for the terminal phenyl ring of oxazolidone derivatives were examined. The results showed that the inhibition potency of these oxazolidone derivatives towards NAAA depends on the sizes, flexibility, and lipophilicity of the terminal groups. SAR results suggested that small lipophilic 3-phenyl substituents or hydroxy-containing 4-phenyl substituents were preferable for optimal potency. Furthermore, the distal aliphatic replacement is also preferred for high inhibitory potency. Rapid dilution and kinetic analysis suggested that oxazolidone derivatives with different terminal phenyl moieties inhibited NAAA via different mechanisms. This study identified several highly potent NAAA inhibitors, including 1a (F215, IC50 = 0.009 μM), 1o (IC50 = 0.061 μM) and 2e (IC50 = 0.092 μM), and also determined structural requirements of oxazolidone derivatives for potent inhibition against NAAA.

1-substituted 4-arylpiperazine as kappa opioid receptor antagonists

Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS

Provided are compounds represented by the formula: where R, Y3, R1,R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2- methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists

There is continuing interest in the discovery and development of new κ opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we report the syntheses of two piperazine JDTic-like analogues. Evaluation of the two compounds in an in vitro [35S] GTPγS binding assay showed that neither compound showed the high potency and κ opioid receptor selectivity of JDTic. A library of compounds using the core scaffold 21 was synthesized and tested for their ability to inhibit [35S]GTPγS binding stimulated by the selective κ opioid agonist U69,593. These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3- methylpiperazin-1-yl]methyl}-2-methylpropyl]-4-phenoxybenzamide (11a), a compound that showed good κ opioid receptor antagonist properties. An SAR study based on 11a provided 28 novel analogues. Evaluation of these 28 compounds in the [35S]GTPγS binding assay showed that several of the analogues were potent and selective κ opioid receptor antagonists.

Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist

S1P3-sparing S1P1 agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P1 and over 5000-fold selectivity against S1P3. The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID 50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P1 and S1P3 showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P3, not in the case of Leu276 in S1P1. This observation gives an explanation for the excellent S1P3-sparing characteristic of CS-2100.